The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...

New research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May) and published in the ...

Patients with diabetes mellitus who use GLP-1 RAs have an increased risk for acute and chronic pancreatitis, according to a study presented at DDW 2025.

Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today an advancement in the use of artificial intelligence (AI) to scale the generation of ...

Researchers used data-driven clustering to define 6 distinct obesity subtypes, offering a potential paradigm shift in how ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, according to a research ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

News Evidence That GLP-1 Drugs Achieve Weight Loss Primarily by Reducing Fat Mass More Than Muscle. Diabetes and obesity have become pressing health issues worldwide. Glucagon-lik ...

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 agonist drugs form part of their treatment, new research being presented at ...

GLP-1 agonist semaglutide is the active ingredient in Novo Nordisk's blockbuster weight-loss drug Wegovy, which achieved sales of around $8 billion last year. Supply constraints have meant that ...

Weight loss jabs, also known as GLP-1 receptor agonists, work by reducing food cravings. Giving obese children weight-loss ...